Compile Data Set for Download or QSAR
Report error Found 228 Enz. Inhib. hit(s) with all data for entry = 10857
TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574745(US11459315, Example 1 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574801(US11459315, Example 1 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574834(US11459315, Example 2 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574835(US11459315, Example 2 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574836(US11459315, Example 3 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574837(US11459315, Example 3 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574838(US11459315, Example 4 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574839(US11459315, Example 4 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574841(US11459315, Example 5 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574842(US11459315, Example 6 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574845(US11459315, Example 7 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574846(US11459315, Example 8)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574847(US11459315, Example 9)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574848(US11459315, Example 10)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM50541902(CHEMBL4635809 | US11459315, Example 11)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM50541895(CHEMBL4639616 | US11459315, Example 12)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574851(US11459315, Example 13)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574852(US11459315, Example 14 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574854(US11459315, Example 15 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574855(US11459315, Example 15 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574856(US11459315, Example 16 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574858(US11459315, Example 17)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574859(US11459315, Example 18 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574860(US11459315, Example 18 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574861(US11459315, Example 19 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574862(US11459315, Example 19 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574863(US11459315, Example 20 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574864(US11459315, Example 20 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574865(US11459315, Example 21 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574866(US11459315, Example 21 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574867(US11459315, Example 22 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574868(US11459315, Example 22 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574870(US11459315, Example 23 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574871(US11459315, Example 24 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574872(US11459315, Example 24 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574873(US11459315, Example 25)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574874(US11459315, Example 26)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574875((R)-1-(1-(4-(3-(difluoromethoxy)azetidin-1-yl)cycl...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574876(US11459315, Example 28 (isomer 1))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574877(US11459315, Example 28 (isomer 2))
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574878(US11459315, Example 29)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574879(US11459315, Example 30)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574881((R)-1-(1-methoxypropan-2-yl)-2-methyl-N-((6-methyl...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574885(1-((R)-1-(4-hydroxycyclohexyl)ethyl)-2-methyl-N-((...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574886(1-((R)-1-(4-hydroxycyclohexyl)ethyl)-2-methyl-N-((...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574887(1-((R)-1-((3R,4R)-3-fluoropiperidin-4-yl)ethyl)-2-...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574888(1-((1R)-1-((3S)-3-fluoropiperidin-4-yl)ethyl)-2-me...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574889((R)-1-(1-(1-cyanopiperidin-4-yl)ethyl)-2-methyl-N-...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574891(7-((R)-1-(4-methoxycyclohexyl)ethyl)-6-methyl-N-((...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574892(7-((R)-1-(4-methoxycyclohexyl)ethyl)-6-methyl-N-((...)
Affinity DataIC50: 0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 228 total ) | Next | Last >>
Jump to: